Skip to main content

Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
bamlanivimab
bamlanivimab etesevimab
casirivimab imdevimab
Health Outcome(s)
utilization
Description

In this report, we examined counts of individuals using the monoclonal antibodies (mAbs) under an Emergency Use Authorization (EUA) in the Rapid Coronavirus-19 Disease (COVID-19) Sentinel Distributed Database (SDD).

The study period includes data from November 1, 2020 to June 30, 2021. We distributed this request to five Sentinel Data Partners on July, 28, 2021.

Deliverables (1)
Sentinel Modular Program Report: Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
November 1, 2020 - June 30, 2021
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Rapidly Refreshed Sentinel Distributed Database (rSSD)
Related Links
Sentinel Drug Analysis: Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Sentinel Drug Analysis: Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Sentinel Drug Analysis: Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Sentinel Drug Analysis: Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis
Sentinel Drug Study: COVID-19 Emergency Use Authorization (EUA) Drugs & Utilization, Anaphylaxis, and Hospitalization